Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies.

12 Jul 2016

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States.

13 Jun 2016

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.

30 Apr 2016

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.

15 Mar 2016

UAB research reveals heterogonous population of leukemia stem cells

University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.

16 Feb 2016

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

The National Comprehensive Cancer Network has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks™ for Breast, Colon, Kidney, and Rectal Cancers.

15 Feb 2016

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Health experts at Johns Hopkins Medicine are calling on lawmakers and regulators to close loopholes in the Orphan Drug Act they claim give drug companies millions of dollars in unintended and misplaced subsidies and tax breaks and fuel skyrocketing medication costs.

20 Nov 2015

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation announced today that Franziska Michor, PhD, is the 2015 recipient of the NYSCF - Robertson Stem Cell Prize for her work pioneering new approaches to study the growth, spread, and treatment of cancer. Her laboratory fuses her passions in mathematics, molecular biology and patient care to investigate how cancers form and progress.

29 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

NCCN reveals new value initiative for CML and Multiple Myeloma

The National Comprehensive Cancer Network, a not-for-profit alliance of 26 of the world's leading cancer centers, today unveiled its new value initiative—the NCCN Evidence Blocks, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myelogenous Leukemia (CML) and Multiple Myeloma.

19 Oct 2015

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Using two complementary analytical approaches, scientists at Whitehead Institute and Broad Institute of MIT and Harvard have for the first time identified the universe of genes in the human genome essential for the survival and proliferation of human cell lines or cultured human cells.

16 Oct 2015

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the completion of enrolment in a global Phase III clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

15 Sep 2015

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

10 Sep 2015

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015.

27 Aug 2015

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

New study reveals protein's critical role in development and progression of AML

A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.

24 Jul 2015

Researchers identify five recurrent fusion genes involved in acute gastritis and cancer

Studying the gastric cancers of 15 Southeast Asian patients, researchers at The Jackson Laboratory, the Genome Institute of Singapore and other institutions identified five recurrent fusion genes, one of which appears to lead to cellular changes involved in acute gastritis and cancer.

10 Jul 2015

PolyU develops novel big data analysis platform for analyzing interactions among cancer genes

The Hong Kong Polytechnic University has achieved a breakthrough in the cancer genomics by developing a novel big data analysis platform for analyzing the interactions among genes. The analysis platform unveils the unregulated patterns of gene network in cancer and discovers potential diagnostic and therapeutic target genes, Nucleophosmin (NPM1) and its associated genes, in Chronic Myelogenous Leukemia (CML).

24 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

UAB research reveals heterogonous population of leukemia stem cells

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

NCCN reveals new value initiative for CML and Multiple Myeloma

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

DelMar closes on $2.6 million registered direct placement

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

New study reveals protein's critical role in development and progression of AML

Researchers identify five recurrent fusion genes involved in acute gastritis and cancer

PolyU develops novel big data analysis platform for analyzing interactions among cancer genes

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in